HomeCompareVECT vs STAG

VECT vs STAG: Dividend Comparison 2026

VECT yields 11.86% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VECT wins by $25.4K in total portfolio value
10 years
VECT
VECT
● Live price
11.86%
Share price
$16.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.7K
Annual income
$2,485.28
Full VECT calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — VECT vs STAG

📍 VECT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVECTSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VECT + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VECT pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VECT
Annual income on $10K today (after 15% tax)
$1,007.71/yr
After 10yr DRIP, annual income (after tax)
$2,112.49/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, VECT beats the other by $1,719.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VECT + STAG for your $10,000?

VECT: 50%STAG: 50%
100% STAG50/50100% VECT
Portfolio after 10yr
$31.0K
Annual income
$1,473.75/yr
Blended yield
4.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

VECT
Analyst Ratings
3
Buy
Consensus: Buy
Price Target
$18.00
+6.7% upside vs current
Range: $18.00 — $18.00
Altman Z
13.9
Piotroski
4/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VECT buys
0
STAG buys
0
No recent congressional trades found for VECT or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVECTSTAG
Forward yield11.86%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3%
Portfolio after 10y$43.7K$18.3K
Annual income after 10y$2,485.28$462.22
Total dividends collected$18.2K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$18.00$45.00

Year-by-year: VECT vs STAG ($10,000, DRIP)

YearVECT PortfolioVECT Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$11,886$1,185.54$10,665$345.09+$1.2KVECT
2$14,034$1,316.89$11,364$357.70+$2.7KVECT
3$16,470$1,453.25$12,098$370.43+$4.4KVECT
4$19,217$1,593.89$12,869$383.28+$6.3KVECT
5$22,300$1,738.05$13,677$396.23+$8.6KVECT
6$25,746$1,884.96$14,524$409.27+$11.2KVECT
7$29,582$2,033.87$15,411$422.41+$14.2KVECT
8$33,837$2,184.03$16,339$435.61+$17.5KVECT
9$38,540$2,334.73$17,311$448.89+$21.2KVECT
10$43,723$2,485.28$18,327$462.22+$25.4KVECT

VECT vs STAG: Complete Analysis 2026

VECTStock

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

Full VECT Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this VECT vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VECT vs SCHDVECT vs JEPIVECT vs OVECT vs KOVECT vs MAINVECT vs PLDVECT vs EQRVECT vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.